Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$0.97
-0.05 (-5.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-23.4M · quality 32.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$259M
P/E
N/A
•EV/EBITDA
5.3x
↓ROE
-16.4%
↓Gross Margin
83.3%
↑Debt/Equity
1.59
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
25.4%
FCF / Net income
-11.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $236.2M · net income $-5.3M · FCF $59.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $236.2M | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M | $294.6M | $335.0M | $207.7M | $181.2M | $1.5M | $0.00 | $0.00 | — | — |
| Net Income | $-5.3M | $-5.3M | $-69.4M | $-51.9M | $-94.2M | $-282.0M | $-384.8M | $-279.7M | $-143.6M | $-73.7M | $-135.7M | $-60.7M | $-37.0M | $-13.2M | $-8.2M |
| EBITDA | $21.7M | $21.7M | $-13.7M | $-8.3M | $-40.8M | $-262.6M | $-375.8M | $-284.0M | $-177.3M | $-76.1M | $-136.2M | $-61.4M | $-37.9M | — | — |
| EPS | -0.02 | -0.02 | -0.33 | -0.28 | -0.51 | -1.70 | -2.78 | -2.36 | — | — | — | — | — | — | — |
| Gross Margin | 83.3% | 83.3% | 60.6% | 61.9% | 70.7% | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 9.9% | 9.9% | -31.5% | -23.7% | -22.2% | -125.0% | -128.2% | -85.5% | -85.8% | -42.3% | -8889.9% | — | — | — | — |
| Net Margin | -2.3% | -2.3% | -43.3% | -26.7% | -32.2% | -133.3% | -130.6% | -83.5% | -69.1% | -40.7% | -8843.5% | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 1.59 | 1.59 | -0.97 | -1.57 | 19.08 | 0.00 | 0.39 | 0.19 | — | — | — | — | — | — | — |
| Current Ratio | 1.40 | 1.40 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $59.9M | $59.9M | $-40.7M | $-23.4M | $-73.3M | $-253.0M | $-110.7M | $-264.1M | $-99.1M | $-57.8M | $55.2M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -16.4% | -16.4% | 141.1% | 169.8% | -1801.6% | -381.1% | -157.5% | -71.2% | -22.6% | -60.1% | -199.3% | -46.3% | -35.6% | 10.4% | 13.8% |
| Valuation | |||||||||||||||
| EV/EBITDA | 5.30 | 5.30 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 7.61 | 7.61 | — | — | 22.44 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 47.5% | 47.5% | -17.7% | -33.5% | — | -28.2% | -12.0% | 61.3% | 14.6% | 11706.3% | — | — | — | — | — |
| EPS Growth | 93.9% | 93.9% | -17.9% | 45.1% | — | 38.8% | -17.8% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-70.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.33 → -0.02
Residual
-70.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.